<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513223</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-A1811-I-102</org_study_id>
    <nct_id>NCT04513223</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics, and Antitumour Activity of SHR-A1811, in Patients With HER2-expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: a Phase 1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, dose escalation, PK expansion and efficacy expansion study&#xD;
      of phase I. The purpose of this study is to assess the tolerability, safety, pharmacokinetics&#xD;
      and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2-expressing&#xD;
      advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT and the recommended Phase 2 dose (RP2D)</measure>
    <time_frame>Subjects will be treated and observed for dose-limiting toxicity(DLT) through the end of the first cycle (Days 1-21).</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>SHR-A1811</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-A1811</intervention_name>
    <description>There are six pre-defined dose regimens . Subjects will be enrolled with an initial dose</description>
    <arm_group_label>SHR-A1811</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a pathologically or cytologically documented advanced/unresectable or metastatic&#xD;
             gastric or gastroesophageal junction adenocarcinoma and colorectal cancer that is&#xD;
             refractory to or intolerable with standard treatment, or for which no standard&#xD;
             treatment is available.&#xD;
&#xD;
          -  At least one evaluable or measurable lesion should be present and identified according&#xD;
             to Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1.&#xD;
&#xD;
          -  Has an ECOG PS 0-1.&#xD;
&#xD;
          -  Has a life expectancy of ≥ 3 months.&#xD;
&#xD;
          -  Has adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has unresolved toxicities from previous anticancer therapy, defined as toxicities not&#xD;
             yet resolved to NCI-CTCAE version 5.0 grade ≤ 1.&#xD;
&#xD;
          -  Has received HER2 antibody drug conjugates,.&#xD;
&#xD;
          -  Central nervous system metastasis or meningeal metastasis with clinical symptoms&#xD;
&#xD;
          -  Has active infection requiring systemic treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>qing yang</last_name>
    <phone>+86 15705155017</phone>
    <email>yangqing@hrglobe.cn</email>
  </overall_contact>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

